Richard B Silverman

List of Publications by Year in Descending Order

255 papers	7,315 citations	42 h-index	68 g-index
277 ext. papers	8,030 ext. citations	7.3 avg, IF	6.09 L-index

#	Paper	IF	Citations
255	Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS).. *Scientific Reports*, **2022**, 12, 1701	4.9	1
254	NU-9 improves health of hSOD1 mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone.. *Scientific Reports*, **2022**, 12, 5383	4.9	0
253	Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 38-49	4.3	2
252	Palladium-Catalyzed Arylation of Cyclic Dicarbonyl Compounds for the Synthesis of Ca1.3 Inhibitors.. *ACS Omega*, **2022**, 7, 14252-14263	3.9	0
251	A Small Peptide Increases Drug Delivery in Human Melanoma Cells. *Pharmaceutics*, **2022**, 14, 1036	6.4	0
250	OV329, a novel highly potent aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats. *Epilepsia*, **2021**, 62, 3091-3104	6.4	1
249	Theoretical and Mechanistic Validation of Global Kinetic Parameters of the Inactivation of GABA Aminotransferase by OV329 and CPP-115. *ACS Chemical Biology*, **2021**, 16, 615-630	4.9	3
248	Remarkable and Unexpected Mechanism for ()-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase. *Journal of the American Chemical Society*, **2021**, 143, 8193-8207	16.4	3
247	Turnover and Inactivation Mechanisms for ()-3-Amino-4,4-difluorocyclopent-1-enecarboxylic Acid, a Selective Mechanism-Based Inactivator of Human Ornithine Aminotransferase. *Journal of the American Chemical Society*, **2021**, 143, 8689-8703	16.4	4
246	Structural and Kinetic Analyses Reveal the Dual Inhibition Modes of Ornithine Aminotransferase by (1,3)-3-Amino-4-(hexafluoropropan-2-ylidenyl)-cyclopentane-1-carboxylic Acid (BCF). *ACS Chemical Biology*, **2021**, 16, 67-75	4.9	4
245	Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology. *Clinical and Translational Medicine*, **2021**, 11, e336	5.7	6
244	Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice. *Current Alzheimer Research*, **2021**, 18, 283-297	3	1
243	Physiological involvement of presynaptic L-type voltage-dependent calcium channels in GABA release of cerebellar molecular layer interneurons. *Journal of Neurochemistry*, **2020**, 155, 390-402	6	4
242	A Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of Aminobutyric Acid. *Journal of the American Chemical Society*, **2020**, 142, 4892-4903	16.4	12
241	Mechanism-Based Design of 3-Amino-4-Halocyclopentenecarboxylic Acids as Inactivators of GABA Aminotransferase. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1949-1955	4.3	4
240	(S)-4-Amino-5-phenoxypentanoate designed as a potential selective agonist of the bacterial transcription factor GabR. *Protein Science*, **2020**, 29, 1816-1828	6.3	1
239	A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca1.3 L-Type Calcium Channels. *ACS Chemical Biology*, **2020**, 15, 2539-2550	4.9	8

238	Inducible nitric oxide synthase: Regulation, structure, and inhibition. *Medicinal Research Reviews*, **2020**, 40, 158-189	14.4	150
237	First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate. *Journal of Medicinal Chemistry*, **2020**, 63, 4528-4554	8.3	6
236	Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold. *Journal of Medicinal Chemistry*, **2019**, 62, 2690-2707	8.3	15
235	Mechanism of Inactivation of Ornithine Aminotransferase by (1,3)-3-Amino-4-(hexafluoropropan-2-ylidenyl)cyclopentane-1-carboxylic Acid. *Journal of the American Chemical Society*, **2019**, 141, 10711-10721	16.4	9
234	A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease. *Science Translational Medicine*, **2019**, 11,	17.5	46
233	Conversion of Quinazoline Modulators from Inhibitors to Activators of Glucocerebrosidase. *Journal of Medicinal Chemistry*, **2019**, 62, 1218-1230	8.3	13
232	Glucocerebrosidase Modulators Promote Dimerization of Glucocerebrosidase and Reveal an Allosteric Binding Site. *Journal of the American Chemical Society*, **2018**, 140, 5914-5924	16.4	20
231	Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction. *Journal of the American Chemical Society*, **2018**, 140, 2151-2164	16.4	31
230	Total Synthesis of Tambromycin Enabled by Indole C-H Functionalization. *Organic Letters*, **2018**, 20, 2369-2373	6.2	20
229	Design and Mechanism of GABA Aminotransferase Inactivators. Treatments for Epilepsies and Addictions. *Chemical Reviews*, **2018**, 118, 4037-4070	68.1	29
228	Synthesis of (S)-3-Amino-4-(difluoromethylenyl)-cyclopent-1-ene-1-carboxylic Acid (OV329), a Potent Inactivator of Aminobutyric Acid Aminotransferase. *Organic Letters*, **2018**, 20, 4589-4592	6.2	7
227	Structural Basis for Isoform Selective Nitric Oxide Synthase Inhibition by Thiophene-2-carboximidamides. *Biochemistry*, **2018**, 57, 6319-6325	3.2	2
226	Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 3958-3978	8.3	20
225	PLP and GABA trigger GabR-mediated transcription regulation in via external aldimine formation. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3891-3896	11.5	20
224	Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker. *Journal of Medicinal Chemistry*, **2017**, 60, 9360-9375	8.3	9
223	Selective Targeting by a Mechanism-Based Inactivator against Pyridoxal 5RPhosphate-Dependent Enzymes: Mechanisms of Inactivation and Alternative Turnover. *Biochemistry*, **2017**, 56, 4951-4961	3.2	12
222	Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 7146-7165	8.3	11
221	Targeting Bacterial Nitric Oxide Synthase with Aminoquinoline-Based Inhibitors. *Biochemistry*, **2016**, 55, 5587-5594	3.2	11

220	Regulation of aldosterone secretion by Cav1.3. *Scientific Reports*, **2016**, 6, 24697	4.9	24
219	Electrostatic Control of Isoform Selective Inhibitor Binding in Nitric Oxide Synthase. *Biochemistry*, **2016**, 55, 3702-7	3.2	25
218	Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker. *Journal of Medicinal Chemistry*, **2016**, 59, 4913-25	8.3	13
217	Design and Synthesis of Potent Quinazolines as Selective Glucocerebrosidase Modulators. *Journal of Medicinal Chemistry*, **2016**, 59, 8508-20	8.3	9
216	2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity. *Journal of Medicinal Chemistry*, **2015**, 58, 5548-60	8.3	17
215	Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase. *Biochemistry*, **2015**, 54, 4075-82	3.2	6
214	Nitric Oxide Synthase as a Target for Methicillin-Resistant Staphylococcus aureus. *Chemistry and Biology*, **2015**, 22, 785-92		13
213	Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. *Journal of Medicinal Chemistry*, **2015**, 58, 5942-9	8.3	10
212	Mechanistic studies of inactivation of inducible nitric oxide synthase by amidines. *Biochemistry*, **2015**, 54, 2530-8	3.2	9
211	Mechanism of Inactivation of Neuronal Nitric Oxide Synthase by (S)-2-Amino-5-(2-(methylthio)acetimidamido)pentanoic Acid. *Journal of the American Chemical Society*, **2015**, 137, 5980-9	16.4	4
210	Design and mechanism of tetrahydrothiophene-based aminobutyric acid aminotransferase inactivators. *Journal of the American Chemical Society*, **2015**, 137, 4525-33	16.4	14
209	Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors. *ACS Medicinal Chemistry Letters*, **2015**, 6, 607-11	4.3	7
208	Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase. *Journal of Medicinal Chemistry*, **2015**, 58, 8694-712	8.3	17
207	Mechanism of Inactivation of GABA Aminotransferase by (E)- and (Z)-(1S,3S)-3-Amino-4-fluoromethylenyl-1-cyclopentanoic Acid. *ACS Chemical Biology*, **2015**, 10, 2087-98	4.9	8
206	Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. *Brain*, **2015**, 138, 3221-37	11.2	51
205	Synthesis of mevalonate- and fluorinated mevalonate prodrugs and their in vitro human plasma stability. *European Journal of Medicinal Chemistry*, **2015**, 90, 448-61	6.8	10
204	Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs. *Medicinal Research Reviews*, **2015**, 35, 286-305	14.4	23
203	The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. *PLoS ONE*, **2015**, 10, e0116919	3.7	82

202	Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase. *ACS Medicinal Chemistry Letters*, **2015**, 6, 840-4	4.3	27
201	Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2015**, 58, 1067-88	8.3	24
200	Mechanism of inactivation of γ-aminobutyric acid aminotransferase by (1S,3S)-3-amino-4-difluoromethylene-1-cyclopentanoic acid (CPP-115). *Journal of the American Chemical Society*, **2015**, 137, 2628-40	16.4	23
199	Structure-based design of bacterial nitric oxide synthase inhibitors. *Journal of Medicinal Chemistry*, **2015**, 58, 994-1004	8.3	13
198	Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 76, 414-26	6.8	25
197	An Accessible Chiral Linker to Enhance Potency and Selectivity of Neuronal Nitric Oxide Synthase Inhibitors. *ACS Medicinal Chemistry Letters*, **2014**, 5, 56-60	4.3	12
196	Potent and selective double-headed thiophene-2-carboximidamide inhibitors of neuronal nitric oxide synthase for the treatment of melanoma. *Journal of Medicinal Chemistry*, **2014**, 57, 686-700	8.3	33
195	Structures of human constitutive nitric oxide synthases. *Acta Crystallographica Section D: Biological Crystallography*, **2014**, 70, 2667-74		28
194	Treatment of amyotrophic lateral sclerosis: lessons learned from many failures. *ACS Medicinal Chemistry Letters*, **2014**, 5, 1179-81	4.3	6
193	Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. *Chemical Society Reviews*, **2014**, 43, 6814-38	58.5	104
192	Combination of chiral linkers with thiophenecarboximidamide heads to improve the selectivity of inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4504-4510	2.9	7
191	Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 5098-101	2.9	8
190	Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition. *Journal of Medicinal Chemistry*, **2014**, 57, 1513-30	8.3	34
189	Nitric oxide synthase inhibitors that interact with both heme propionate and tetrahydrobiopterin show high isoform selectivity. *Journal of Medicinal Chemistry*, **2014**, 57, 4382-96	8.3	15
188	The mobility of a conserved tyrosine residue controls isoform-dependent enzyme-inhibitor interactions in nitric oxide synthases. *Biochemistry*, **2014**, 53, 5272-9	3.2	13
187	nNOS inhibition during profound asphyxia reduces seizure burden and improves survival of striatal phenotypic neurons in preterm fetal sheep. *Neuropharmacology*, **2014**, 83, 62-70	5.5	18
186	Two continuous coupled assays for ornithine-δ-aminotransferase. *Analytical Biochemistry*, **2013**, 440, 145-9	3.1	11
185	A novel synthesis of 1-aryl-3-piperidone derivatives. *Tetrahedron Letters*, **2013**, 54, 573-575	2	7

184	Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 1333-43	3.4	14
183	Structural and biological studies on bacterial nitric oxide synthase inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 18127-31	11.5	38
182	Structure-guided design of selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2013**, 56, 3024-32	8.3	25
181	Probing the steric requirements of the □-aminobutyric acid aminotransferase active site with fluorinated analogues of vigabatrin. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 903-11	3.4	11
180	Case Study 3: Fragment Hopping to Design Highly Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors. *Methods and Principles in Medicinal Chemistry*, **2013**, 279-296	0.4	
179	Partial neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep. *Experimental Neurology*, **2013**, 250, 282-92	5.7	18
178	Chiral linkers to improve selectivity of double-headed neuronal nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5674-9	2.9	9
177	In search of potent and selective inhibitors of neuronal nitric oxide synthase with more simple structures. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 5323-31	3.4	7
176	Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. *Journal of Medicinal Chemistry*, **2013**, 56, 3121-47	8.3	102
175	Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. *Journal of Medicinal Chemistry*, **2013**, 56, 2665-75	8.3	14
174	Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 4365-73	3.4	25
173	Structure-activity relationship of N,NRdisubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson□s disease. *Journal of Medicinal Chemistry*, **2013**, 56, 4786-97	8.3	24
172	Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma. *Antioxidants and Redox Signaling*, **2013**, 19, 433-47	8.4	41
171	Recent advances toward improving the bioavailability of neuronal nitric oxide synthase inhibitors. *Current Topics in Medicinal Chemistry*, **2013**, 13, 803-12	3	6
170	Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 1029-45	3.4	18
169	Intramolecular hydrogen bonding: a potential strategy for more bioavailable inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 2435-43	3.4	28
168	Acid-Facilitated Debenzylation of N-Boc, N-Benzyl Double Protected 2-Aminopyridinomethylpyrrolidine Derivatives. *Tetrahedron*, **2012**, 68, 1359-1366	2.4	11
167	High yielding allylation of a chiral secondary alcohol containing base sensitive functional groups. *Tetrahedron Letters*, **2012**, 53, 1319-1322	2	3

166	Direct amination of α-halo-α-ketoesters with anilines. *Journal of Organic Chemistry*, **2012**, 77, 3462-7	4.2	4
165	CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. *Nature Communications*, **2012**, 3, 1146	17.4	114
164	Selective monocationic inhibitors of neuronal nitric oxide synthase. Binding mode insights from molecular dynamics simulations. *Journal of the American Chemical Society*, **2012**, 134, 11559-72	16.4	20
163	(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction. *Journal of Medicinal Chemistry*, **2012**, 55, 357-66	8.3	36
162	Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 5763-73	3.4	14
161	The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. *Cell Reports*, **2012**, 2, 1492-7	10.6	137
160	The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms. *Journal of Medicinal Chemistry*, **2012**, 55, 567-75	8.3	27
159	Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS. *ACS Medicinal Chemistry Letters*, **2012**, 3, 584-587	4.3	15
158	ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. *Journal of Medicinal Chemistry*, **2012**, 55, 515-27	8.3	36
157	Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2011**, 12, 87-96		29
156	Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. *Journal of Medicinal Chemistry*, **2011**, 54, 2409-21	8.3	34
155	Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2011**, 54, 2039-48	8.3	33
154	Synthesis of (S)-2-Boc-Amino-8-(R)-(tert-butyldimethylsilanyloxy) decanoic acid, a Precursor to the Unusual Amino Acid Residue of the Anticancer Agent Microsporin B. *Tetrahedron Letters*, **2011**, 52, 5438-5440	2	5
153	Improved synthesis of chiral pyrrolidine inhibitors and their binding properties to neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2011**, 54, 6399-403	8.3	8
152	Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 613-22	3.4	16
151	Temperature-dependent spin crossover in neuronal nitric oxide synthase bound with the heme-coordinating thioether inhibitors. *Journal of the American Chemical Society*, **2011**, 133, 8326-34	16.4	13
150	Involvement of neuronal nitric oxide synthase in ongoing fetal brain injury following near-term rabbit hypoxia-ischemia. *Developmental Neuroscience*, **2011**, 33, 288-98	2.2	18
149	Neuronal nitric oxide synthase inhibition prevents cerebral palsy following hypoxia-ischemia in fetal rabbits: comparison between JI-8 and 7-nitroindazole. *Developmental Neuroscience*, **2011**, 33, 312-9	2.2	28

148	Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae. *Journal of Biological Chemistry*, **2010**, 285, 20654-63	5.4	11
147	Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model. *Journal of the American Chemical Society*, **2010**, 132, 5437-42	16.4	46
146	Chiral discrimination among aminotransferases: inactivation by 4-amino-4,5-dihydrothiophenecarboxylic acid. *Biochemistry*, **2010**, 49, 3138-47	3.2	11
145	Mechanism of inactivation of Escherichia coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid. *Biochemistry*, **2010**, 49, 10507-15	3.2	5
144	Potent, highly selective, and orally bioavailable gem-difluorinated monocationic inhibitors of neuronal nitric oxide synthase. *Journal of the American Chemical Society*, **2010**, 132, 14229-38	16.4	47
143	Heme-coordinating inhibitors of neuronal nitric oxide synthase. Iron-thioether coordination is stabilized by hydrophobic contacts without increased inhibitor potency. *Journal of the American Chemical Society*, **2010**, 132, 798-806	16.4	18
142	Role of zinc in isoform-selective inhibitor binding to neuronal nitric oxide synthase. *Biochemistry*, **2010**, 49, 10803-10	3.2	33
141	Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. *Journal of Medicinal Chemistry*, **2010**, 53, 7804-24	8.3	40
140	An Alkoxide Anion Triggered tert-Butyloxycarbonyl Group Migration. Mechanism and Application. *Tetrahedron Letters*, **2010**, 51, 2536-2538	2	8
139	Mevalonate analogues as substrates of enzymes in the isoprenoid biosynthetic pathway of Streptococcus pneumoniae. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 1124-34	3.4	14
138	Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 3147-58	3.4	35
137	Structure-based design, synthesis, and biological evaluation of lipophilic-tailed monocationic inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 6526-37	3.4	15
136	Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 554-7	2.9	25
135	Peripheral but crucial: a hydrophobic pocket (Tyr(706), Leu(337), and Met(336)) for potent and selective inhibition of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 6258-61	2.9	17
134	Synthesis and enzymatic evaluation of 2- and 4-aminothiazole-based inhibitors of neuronal nitric oxide synthase. *Beilstein Journal of Organic Chemistry*, **2009**, 5, 28	2.5	11
133	Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. *Annals of Neurology*, **2009**, 65, 209-17	9.4	71
132	Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood-brain barrier penetration. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 7593-605	3.4	9
131	Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 2371-80	3.4	36

130	A cellular model for screening neuronal nitric oxide synthase inhibitors. *Analytical Biochemistry*, **2009**, 390, 74-8	3.1	14
129	Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. *Journal of Medicinal Chemistry*, **2009**, 52, 779-97	8.3	78
128	Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases. *Accounts of Chemical Research*, **2009**, 42, 439-51	24.3	104
127	Concise route to the chiral pyrrolidine core of selective inhibitors of neuronal nitric oxide. *Organic Letters*, **2009**, 11, 5194-7	6.2	8
126	Crystal structures of constitutive nitric oxide synthases in complex with de novo designed inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 2060-6	8.3	18
125	Hypoxia-ischemia causes persistent movement deficits in a perinatal rabbit model of cerebral palsy: assessed by a new swim test. *International Journal of Developmental Neuroscience*, **2009**, 27, 549-57	2.7	27
124	L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 4533-7	8.3	10
123	Revisiting heme mechanisms. A perspective on the mechanisms of nitric oxide synthase (NOS), Heme oxygenase (HO), and cytochrome P450s (CYP450s). *Biochemistry*, **2008**, 47, 2231-43	3.2	93
122	Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. *Journal of the American Chemical Society*, **2008**, 130, 3900-14	16.4	88
121	From basic science to blockbuster drug: the discovery of Lyrica. *Angewandte Chemie - International Edition*, **2008**, 47, 3500-4	16.4	109
120	Synthesis and evaluation of novel aromatic substrates and competitive inhibitors of GABA aminotransferase. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3122-5	2.9	19
119	Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for gamma-aminobutyric acid aminotransferase. Conformational probes for GABA binding. *Biochemistry*, **2007**, 46, 13819-28	3.2	35
118	Inactivation of Escherichia coli L-aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-thiophenecarboxylic acid reveals "a tale of two mechanisms". *Biochemistry*, **2007**, 46, 10517-27	3.2	14
117	Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. *Journal of Medicinal Chemistry*, **2007**, 50, 2089-99	8.3	28
116	Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A. *Tetrahedron*, **2007**, 63, 6535-6541	2.4	61
115	Selective L-nitroargininylaminopyrrolidine and L-nitroargininylaminopiperidine neuronal nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 1928-38	3.4	20
114	Hydroxyethylene isosteres of selective neuronal nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 6096-108	3.4	6
113	Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferase. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1651-4	2.9	19

112	Fluorinated conformationally restricted gamma-aminobutyric acid aminotransferase inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 7404-12	8.3	46
111	(+/-)-(1S,2R,5S)-5-Amino-2-fluorocyclohex-3-enecarboxylic acid. A potent GABA aminotransferase inactivator that irreversibly inhibits via an elimination-aromatization pathway. *Biochemistry*, **2006**, 45, 14513-22	3.2	16
110	Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 6254-63	8.3	22
109	New substrates and inhibitors of gamma-aminobutyric acid aminotransferase containing bioisosteres of the carboxylic acid group: design, synthesis, and biological activity. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 1331-8	3.4	33
108	Syntheses and evaluation of fluorinated conformationally restricted analogues of GABA as potential inhibitors of GABA aminotransferase. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 2242-52	3.4	30
107	Design, synthesis, and biological testing of potential heme-coordinating nitric oxide synthase inhibitors. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3185-98	3.4	17
106	Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3320-9	3.4	42
105	Hydroxyl-terminated peptidomimetic inhibitors of neuronal nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3681-90	3.4	6
104	Remote protection prevents unwanted cyclizations with 2-aminopyridines. *Tetrahedron Letters*, **2006**, 47, 6113-6115	2	15
103	Mechanism of inactivation of inducible nitric oxide synthase by amidines. Irreversible enzyme inactivation without inactivator modification. *Journal of the American Chemical Society*, **2005**, 127, 858-68	16.4	43
102	Exploring the binding conformations of bulkier dipeptide amide inhibitors in constitutive nitric oxide synthases. *Biochemistry*, **2005**, 44, 15222-9	3.2	18
101	Selective neuronal nitric oxide synthase inhibitors. *Current Topics in Medicinal Chemistry*, **2005**, 5, 603-24	3	60
100	Synthesis of cyclopropane isosteres of the antiepilepsy drug vigabatrin and evaluation of their inhibition of GABA aminotransferase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 293-301	5.6	5
99	Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5Rphosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin. *Journal of Biological Chemistry*, **2004**, 279, 363-73	5.4	111
98	Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. *Nature Structural and Molecular Biology*, **2004**, 11, 54-9	17.6	72
97	Conformationally-restricted vigabatrin analogs as irreversible and reversible inhibitors of gamma-aminobutyric acid aminotransferase. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 5719-25	3.4	14
96	Inactivation of gamma-aminobutyric acid aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid does not proceed by the expected aromatization mechanism. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 203-6	2.9	11
95	Structures of the neuronal and endothelial nitric oxide synthase heme domain with D-nitroarginine-containing dipeptide inhibitors bound. *Biochemistry*, **2004**, 43, 5181-7	3.2	28

94	Mechanistic crystallography. Mechanism of inactivation of gamma-aminobutyric acid aminotransferase by (1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid as elucidated by crystallography. *Biochemistry*, **2004**, 43, 14057-63	3.2	23
93	Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors. *Journal of Medicinal Chemistry*, **2004**, 47, 703-10	8.3	29
92	A mechanism for substrate-Induced formation of 6-hydroxyflavin mononucleotide catalyzed by C30A trimethylamine dehydrogenase. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 4129-32	2.9	8
91	Inactivation of mitochondrial monoamine oxidase B by methylthio-substituted benzylamines. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 4423-30	3.4	16
90	Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2003**, 46, 1661-9	8.3	40
89	Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. *Journal of Medicinal Chemistry*, **2003**, 46, 5700-11	8.3	65
88	Design, synthesis, and biological activity of a difluoro-substituted, conformationally rigid vigabatrin analogue as a potent gamma-aminobutyric acid aminotransferase inhibitor. *Journal of Medicinal Chemistry*, **2003**, 46, 5292-3	8.3	119
87	Purification and inactivation of 3-hydroxyanthranilic acid 3,4-dioxygenase from beef liver. *International Journal of Biochemistry and Cell Biology*, **2003**, 35, 1085-97	5.6	7
86	Inactivation and inhibition of gamma-aminobutyric acid aminotransferase by conformationally restricted vigabatrin analogues. *Journal of Medicinal Chemistry*, **2002**, 45, 4531-9	8.3	31
85	Design of a conformationally restricted analogue of the antiepilepsy drug Vigabatrin that directs its mechanism of inactivation of gamma-aminobutyric acid aminotransferase. *Journal of the American Chemical Society*, **2002**, 124, 1620-4	16.4	31
84	Solid-phase, Pd-catalyzed silicon-aryl carbon bond formation. Synthesis of sansalvamide A peptide. *Organic Letters*, **2002**, 4, 4171-4	6.2	55
83	Silicon-based aromatic transferring linkers for traceless solid-phase synthesis of aryl-, polyaryl-, and heteroaryl-containing compounds. *Tetrahedron*, **2001**, 57, 5339-5352	2.4	23
82	Inactivation of monoamine oxidase B by 1-phenylcyclopropylamine: mass spectral evidence for the flavin adduct. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1757-60	2.9	12
81	Mechanism of nitric oxide synthase. Evidence that direct hydrogen atom abstraction from the O-H bond of NG-hydroxyarginine is not relevant to the mechanism. *Journal of the American Chemical Society*, **2001**, 123, 2674-6	16.4	58
80	Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoakyl]aminopentyl)-NRnitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **2001**, 44, 2667-70	8.3	65
79	Mild and selective sodium azide mediated cleavage of p-nitrobenzoic esters. *Organic Letters*, **2001**, 3, 2477-9	6.2	37
78	Synthesis and evaluation of dipeptide amides containing N omega-nitroarginine and D-2,4-diaminobutyric acids as inhibitors of neuronal nitric oxide synthase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2001**, 16, 233-9		6
77	Short, highly efficient syntheses of protected 3-azido- and 4-azidoproline and their precursors. *Organic Letters*, **2001**, 3, 2481-4	6.2	54

76	The multiple active enzyme species of gamma-aminobutyric acid aminotransferase are not isozymes. *Archives of Biochemistry and Biophysics*, **2000**, 374, 248-54	4.1	12
75	Anomalous Schmidt reaction products of phenylacetic acid and derivatives. *Perkin Transactions II RSC*, **2000**, 55-59		9
74	Traceless solid-phase synthesis of chiral 3-aryl beta-amino acid containing peptides using a side-chain-tethered beta-amino acid building block. *Organic Letters*, **2000**, 2, 303-6	6.2	28
73	ENDOR Spectroscopic Evidence for the Geometry of Binding ofretro-inverso-N-Nitroarginine-Containing Dipeptide Amides to Neuronal Nitric Oxide Synthase. *Journal of the American Chemical Society*, **2000**, 122, 7869-7875	16.4	13
72	Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases. *Journal of Medicinal Chemistry*, **2000**, 43, 2938-45	8.3	32
71	Rapid, high-yield, solid-phase synthesis of the antitumor antibiotic sansalvamide A using a side-chain-tethered phenylalanine building block. *Organic Letters*, **2000**, 2, 3743-6	6.2	41
70	A new class of conformationally rigid analogues of 4-amino-5-halopentanoic acids, potent inactivators of gamma-aminobutyric acid aminotransferase. *Journal of Medicinal Chemistry*, **2000**, 43, 706-20	8.3	104
69	Selective Inhibition of Monoamine Oxidase B by Aminoethyl Substituted Benzyl Ethers. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1999**, 15, 11-21		1
68	Isolation and characterization of the product of inactivation of gamma-aminobutyric acid aminotransferase by gabaculine. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1581-90	3.4	24
67	Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1941-51	3.4	27
66	Mechanism of Inactivation of -Aminobutyric Acid Aminotransferase by (S)-4-Amino-4,5-dihydro-2-thiophenecarboxylic Acid. *Journal of the American Chemical Society*, **1999**, 121, 7751-7759	16.4	15
65	Mechanistic Studies of the Inactivation of Inducible Nitric Oxide Synthase by N5-(1-Iminoethyl)-l-ornithine (l-NIO). *Journal of the American Chemical Society*, **1999**, 121, 903-916	16.4	26
64	Inhibition and substrate activity of conformationally rigid vigabatrin analogues with gamma-aminobutyric acid aminotransferase. *Journal of Medicinal Chemistry*, **1999**, 42, 4725-8	8.3	33
63	Efficient Solid-Phase Synthesis of Compounds Containing Phenylalanine and Its Derivatives via Side-Chain Attachment to the Polymer Support. *Journal of the American Chemical Society*, **1999**, 121, 8407-8408	16.4	30
62	N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase. *Journal of Medicinal Chemistry*, **1999**, 42, 3147-53	8.3	72
61	An Aromatization Mechanism of Inactivation of -Aminobutyric Acid Aminotransferase for the Antibiotic l-Cycloserine. *Journal of the American Chemical Society*, **1998**, 120, 2256-2267	16.4	34
60	Monoamine Oxidase B-Catalyzed Reactions of cis- and trans-5-Aminomethyl-3-(4-Methoxyphenyl)dihydrofuran-2(3H)-ones. Evidence for a Reversible Redox Reaction. *Journal of the American Chemical Society*, **1998**, 120, 10583-10587	16.4	3
59	Effect of the locus of the oxygen atom in amino ethers on the inactivation of monoamine oxidase B. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1998**, 13, 31-9		4

58	Mechanism of Inactivation of Neuronal Nitric Oxide Synthase by N□Allyl-l-Arginine. *Journal of the American Chemical Society*, **1997**, 119, 10888-10902	16.4	26
57	Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-L-arginine. *Journal of Medicinal Chemistry*, **1997**, 40, 3869-70	8.3	174
56	4-substituted cubylcarbinylamines: a new class of mechanism-based monoamine oxidase B inactivators. *Journal of Medicinal Chemistry*, **1997**, 40, 1165-8	8.3	14
55	Identification of the Active Site Cysteine in Bovine Liver Monoamine Oxidase B. *Journal of the American Chemical Society*, **1997**, 119, 6690-6691	16.4	41
54	Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters. *Journal of Medicinal Chemistry*, **1997**, 40, 2813-7	8.3	41
53	Inactivation of monoamine oxidase B by benzyl 1-(aminomethyl) cyclopropane-1-carboxylate. *Bioorganic and Medicinal Chemistry*, **1997**, 5, 297-304	3.4	11
52	Unusual Mechanistic Difference in the Inactivation of □Aminobutyric Acid Aminotransferase by (E)- and (Z)-4-Amino-6-fluoro-5-hexenoic Acid. *Journal of the American Chemical Society*, **1996**, 118, 1253-1261	16.4	26
51	Mechanisms of Inactivation of □Aminobutyric Acid Aminotransferase by 4-Amino-5-fluoro-5-hexenoic Acid. *Journal of the American Chemical Society*, **1996**, 118, 1241-1252	16.4	26
50	3-substituted alanines inactivate □aminobutyric acid aminotransferase by the same mechanism as do 4-amino-5-halopentanoic acid analogues. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 143-146	2.9	2
49	Inactivation of □aminobutyric acid aminotransferase by (Z)-4-amino-6-fluoro-5-hexenoic acid: Identification of an active site residue. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 1319-1322	2.9	2
48	Mechanism-based inactivation of gamma-aminobutyric acid aminotransferase by 3-amino-4-fluorobutanoic acid. *Bioorganic and Medicinal Chemistry*, **1996**, 4, 1521-35	3.4	4
47	Inactivation of gamma-aminobutyric acid aminotransferase by L-3-chloroalanine hydroxamate. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 11-8	3.4	6
46	SAR studies of fluorine-substituted benzylamines and substituted 2-phenylethylamines as substrates and inactivators of monoamine oxidase B. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1995**, 9, 203-15		11
45	Mechanism-based enzyme inactivators. *Methods in Enzymology*, **1995**, 249, 240-83	1.7	267
44	Radical Ideas about Monoamine Oxidase. *Accounts of Chemical Research*, **1995**, 28, 335-342	24.3	232
43	Monoamine oxidase-catalyzed oxidative decarboxylation of cis- and trans-5-aminomethyl-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one. Evidence for the intermediacy of an .alpha.-radical. *Journal of the American Chemical Society*, **1995**, 117, 12895-12896	16.4	12
42	Synthesis of N-Carbobenzoxy-N,N-acetals. *Synthetic Communications*, **1993**, 23, 1467-1471	1.7	3
41	Mechanism-based enzyme inactivation via a diactivated cyclopropane intermediate. *Journal of the American Chemical Society*, **1993**, 115, 2982-2983	16.4	16

40	The anti-ulcer drug ranitidine hydrochloride and its synthetic intermediates are inactivators of monoamine oxidase-B. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1993**, 7, 43-5		
39	Beta-lactams: a new class of conformationally-rigid inhibitors of gamma-aminobutyric acid aminotransferase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1992**, 6, 125-9		4
38	Inactivation of gamma-aminobutyric acid aminotransferase by various amine buffers. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1992**, 6, 195-9		6
37	4-(Aminomethyl)-1-aryl-2-pyrrolidinones, a new class of monoamine oxidase B inactivators. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1992**, 6, 223-31		10
36	Amino acid analogues as mechanism-based inactivators of aminobutyric acid aminotransferase. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 1371-1374	2.9	3
35	3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. *Epilepsy Research*, **1992**, 11, 103-10	3	82
34	The use of mechanism-based inactivators to probe the mechanism of monoamine oxidase. *Biochemical Society Transactions*, **1991**, 19, 201-6	5.1	26
33	3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase. *Journal of Medicinal Chemistry*, **1991**, 34, 2295-8	8.3	89
32	4-(Oxoalkyl)-substituted GABA analogues as inactivators and substrates of GABA aminotransferase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1991**, 5, 199-205		3
31	Mechanisms of inactivation of .gamma.-aminobutyric acid aminotransferase by the antiepilepsy drug .gamma.-vinyl GABA (vigabatrin). *Journal of the American Chemical Society*, **1991**, 113, 9341-9349	16.4	90
30	Mechanism of inactivation of .gamma.-aminobutyric acid aminotransferase by 4-amino-5-hexynoic acid (.gamma.-ethynyl GABA). *Journal of the American Chemical Society*, **1991**, 113, 9329-9340	16.4	25
29	Chemoenzymatic Synthesis of (R)- and (S)-4-Amino-3-Methylbutanoic Acids. *Synthetic Communications*, **1990**, 20, 159-166	1.7	14
28	Effect of N-ethylmaleimide on beef and rat liver vitamin K1 epoxide reductase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1990**, 3, 289-94		2
27	Mechanism of inactivation of monoamine oxidase B by (aminomethyl)trimethylsilane. *Journal of the American Chemical Society*, **1990**, 112, 4499-4507	16.4	27
26	Synthesis of 2-Substituted-3-Phytyl-1,4-naphthoquinone Epoxides. *Synthetic Communications*, **1990**, 20, 431-438	1.7	4
25	A Convenient Synthesis of 3-Alkyl-4-aminobutanoic Acids. *Synthesis*, **1989**, 1989, 953-955	2.9	36
24	Design of potential anticonvulsant agents: mechanistic classification of GABA aminotransferase inactivators. *Journal of Medicinal Chemistry*, **1989**, 32, 2413-21	8.3	72
23	Inactivation of gamma-aminobutyric acid aminotransferase by (Z)-4-amino-2-fluorobut-2-enoic acid. *Biochemistry*, **1988**, 27, 3285-9	3.2	18

22	Mechanism of inactivation of gamma-aminobutyric acid aminotransferase by (S,E)-4-amino-5-fluoropent-2-enoic acid. *Biochemical and Biophysical Research Communications*, **1988**, 150, 942-6	3.4	17
21	The potential use of mechanism-based enzyme inactivators in medicine. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1988**, 2, 73-90		35
20	Inactivation of gamma-aminobutyric acid aminotransferase by (S,E)-4-amino-5-fluoropent-2-enoic acid and effect on the enzyme of (E)-3-(1-aminocyclopropyl)-2-propenoic acid. *Journal of Medicinal Chemistry*, **1986**, 29, 1840-6	8.3	23
19	Identification of the amino acid bound to the labile adduct formed during inactivation of monoamine oxidase by 1-phenylcyclopropylamine. *Biochemical and Biophysical Research Communications*, **1986**, 135, 154-9	3.4	32
18	Mechanism of inactivation of gamma-aminobutyrate aminotransferase by 4-amino-5-fluoropentanoic acid. First example of an enamine mechanism for a gamma-amino acid with a partition ratio of 0. *Biochemistry*, **1986**, 25, 6817-20	3.2	42
17	4-Amino-2-(substituted methyl)-2-butenoic acids: substrates and potent inhibitors of gamma-aminobutyric acid aminotransferase. *Journal of Medicinal Chemistry*, **1986**, 29, 764-70	8.3	19
16	An Efficient Synthesis of 3-Amino-4-Fluorobutanoic Acid, an Inactivator of GABA Transaminase. *Synthetic Communications*, **1985**, 15, 377-383	1.7	6
15	Mechanism of inactivation of monoamine oxidase by 1-phenylcyclopropylamine. *Biochemistry*, **1985**, 24, 2128-38	3.2	73
14	Revised mechanism for inactivation of mitochondrial monoamine oxidase by N-cyclopropylbenzylamine. *Biochemistry*, **1985**, 24, 6538-43	3.2	32
13	The organic chemistry of mechanism-based enzyme inhibition: a chemical approach to drug design. *Medicinal Research Reviews*, **1984**, 4, 415-47	14.4	28
12	Mechanism-based inactivation of mitochondrial monoamine oxidase by N-(1-methylcyclopropyl)benzylamine. *Biochemistry*, **1984**, 23, 1322-32	3.2	58
11	Effect of alpha-methylation on inactivation of monoamine oxidase by N-cyclopropylbenzylamine. *Biochemistry*, **1984**, 23, 5206-13	3.2	33
10	In vitro and in vivo effects on brain GABA metabolism of (S)-4-amino-5-fluoropentanoic acid, a mechanism-based inactivator of gamma-aminobutyric acid transaminase. *Life Sciences*, **1983**, 32, 2717-23	6.8	5
9	Mechanism of inactivation of gamma-aminobutyric acid-alpha-ketoglutaric acid aminotransferase by 4-amino-5-halopentanoic acids. *Biochemistry*, **1981**, 20, 1197-203	3.2	62
8	In vivo inactivation of gamma-aminobutyric acid-alpha-ketoglutarate transaminase by 4-amino-5-fluoropentanoic acid. *Biochemical and Biophysical Research Communications*, **1981**, 102, 520-3	3.4	9
7	N-(1-Methyl)cyclopropylbenzylamine: a novel inactivator of mitochondrial monoamine oxidase. *Biochemical and Biophysical Research Communications*, **1981**, 101, 1396-401	3.4	27
6	Syntheses of N-[1-2H]- and N-[1-3H]-cyclopropylbenzylamine and [phenyl-14C]-N-cyclopropylbenzylamine. *Journal of Labelled Compounds and Radiopharmaceuticals*, **1981**, 18, 781-790	1.9	2
5	Syntheses of (S)-5-substituted 4-aminopentanoic acids: a new class of .gamma.-aminobutyric acid transaminase inactivators. *Journal of Organic Chemistry*, **1980**, 45, 815-818	4.2	108

4	Irreversible inactivation of pig brain gamma-aminobutyric acid-alpha-ketoglutarate transaminase by 4-amino-5-halopentanoic acids. *Biochemical and Biophysical Research Communications*, **1980**, 95, 250-5	3.4	37
3	Synthesis of [carboxyl -14C] 5 - fluoroorotic acid. *Journal of Labelled Compounds and Radiopharmaceuticals*, **1979**, 16, 361-364	1.9	1
2	Reaction of diethyl acetonedicarboxylate with nitrosyl chloride. *Journal of Heterocyclic Chemistry*, **1978**, 15, 1519-1520	1.9	2
1	Mechanism of inactivation of gamma-cystathionase by beta,beta,beta-trifluoroalanine. *Biochemistry*, **1977**, 16, 5515-20	3.2	41